 Connection
Kathryn Horwitz to Tamoxifen
This is a "connection" page, showing publications Kathryn Horwitz has written about Tamoxifen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.731 |
|
|
|
-
Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501.
Score: 0.276
-
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol. 2000 Nov 30; 74(5):255-9.
Score: 0.167
-
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids. 2000 Oct-Nov; 65(10-11):579-84.
Score: 0.165
-
Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, Horwitz KB. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol. 1999 Apr-Jun; 69(1-6):45-50.
Score: 0.148
-
Miller MM, James RA, Richer JK, Gordon DF, Wood WM, Horwitz KB. Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. J Clin Endocrinol Metab. 1997 Sep; 82(9):2956-61.
Score: 0.133
-
Horwitz KB. When tamoxifen turns bad. Endocrinology. 1995 Mar; 136(3):821-3.
Score: 0.112
-
Horwitz KB. Hormone-resistant breast cancer or "feeding the hand that bites you". Prog Clin Biol Res. 1994; 387:29-45.
Score: 0.103
-
Horwitz KB. Can hormone "resistant" breast cancer cells be inappropriately stimulated by tamoxifen? Ann N Y Acad Sci. 1993 Jun 11; 684:63-74.
Score: 0.099
-
Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat. 1993; 26(2):119-30.
Score: 0.096
-
Graham ML, Smith JA, Jewett PB, Horwitz KB. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 1992 Feb 01; 52(3):593-602.
Score: 0.090
-
Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006 Feb; 147(2):700-13.
Score: 0.058
-
Horwitz KB. Bringing estrogen receptors under control. Breast Cancer Res. 1999; 1(1):5-7.
Score: 0.038
-
Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem. 1978 Nov 25; 253(22):8185-91.
Score: 0.036
-
Horwitz KB. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol. 1994 Jun; 49(4-6):295-302.
Score: 0.027
-
Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013 Jan; 137(2):431-48.
Score: 0.024
-
Horwitz KB. Cellular heterogeneity and mutant oestrogen receptors in hormone resistant breast cancer. Cancer Surv. 1992; 14:41-54.
Score: 0.022
-
Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 1990 Oct 01; 50(19):6208-17.
Score: 0.021
-
Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55.
Score: 0.020
-
Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88.
Score: 0.017
-
Sedlacek SM, Horwitz KB. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids. 1984 Dec; 44(6):467-84.
Score: 0.014
-
Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
Score: 0.013
-
Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 2004 Mar 15; 64(6):2238-44.
Score: 0.013
-
Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000 Apr 18; 101(15):1792-8.
Score: 0.010
-
Horwitz KB, McGuire WL. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer. Recent Results Cancer Res. 1980; 71:45-58.
Score: 0.010
-
Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol. 1979; 117:95-110.
Score: 0.009
-
Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978 Nov; 103(5):1742-51.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|